Evidence map›Paper›PMID 41098679›Full record

ReviewJournal of inflammation research2025

Emerging Insights into the Role of Macrophages in Multiple Sclerosis: Pathogenesis and Potential Therapeutic Strategies.

Jundong Yang, Ziyue Fu, Qiyuan Zou, Zhaoyinqian Li, Yuhan Xing

Abstract readReview
In one paragraph

Review in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jundong Yang *School of Public Health (Shenzhen), Sun Yat-Sen University, Shenzhen, Guangdong Province, 518107, People's Republic of China.
Ziyue Fu *Clinical Medical College, Southwest Medical University, Luzhou, Sichuan Province, People's Republic of China.
Qiyuan ZouDepartment of Otorhinolaryngology, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Children's Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Zhaoyinqian LiDepartment of Laboratory Medicine, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, People's Republic of China.ORCID 0000-0002-1644-5544
Yuhan XingSchool of Public Health (Shenzhen), Sun Yat-Sen University, Shenzhen, Guangdong Province, 518107, People's Republic of China.ORCID 0000-0002-2373-5101

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic, autoimmune, demyelinating disease of the central nervous system (CNS) in which macrophages play a pivotal and multifaceted role. These highly plastic immune cells are key effectors in the immunopathology of MS, contributing to both inflammatory-driven demyelination and subsequent tissue repair. Historically, macrophage function was viewed through the binary lens of pro-inflammatory M1 and anti-inflammatory M2 polarization. However, recent research reveals a far more complex spectrum of activation states within the dynamic microenvironment of MS lesions. Understanding the intricate signals and molecular pathways that govern macrophage polarization in the CNS represents a critical frontier for therapeutic innovation. Interventions aimed at rebalancing macrophage phenotypes have yielded encouraging results in preclinical models, and some therapeutic agents are now advancing into clinical trials. Future investigations are focused on the diverse functions of macrophages in MS pathogenesis, including their involvement in oxidative stress, antigen presentation, and myelin debris clearance. A particularly innovative approach involves harnessing macrophages as cellular vehicles for targeted drug delivery across the blood-brain barrier, offering a potential solution to one of the most significant challenges in CNS therapeutics. The primary challenge now lies in the safe and effective clinical translation of these macrophage-centered therapies. Successfully navigating this transition from bench to bedside holds the potential to deliver transformative treatments that can halt disease progression and restore neurological function for individuals living with this debilitating disease.

Indexed as

central nervous systemmacrophagemultiple sclerosistherapy

Identifiers

PMID41098679
PMCPMC12520004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.